|Bid||39.66 x 1200|
|Ask||39.67 x 900|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||0.83|
|PE Ratio (TTM)||48.81|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
After QIAGEN N.V.'s (NYSE:QGEN) earnings announcement in March 2019, analysts seem fairly confident, as a 19% increase...
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
How do we determine whether Qiagen NV (NYSE:QGEN) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
Qiagen NV NYSE:QGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $694 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN N.V. (NYSE:QGEN), which is in the life sciences business, and is based in Netherlands, saw significant share...
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
Stocks that moved substantially or traded heavily on Monday: Alphabet Inc., down $24.12 to $1,144.66 The parent of search engine Google warned that some of its features could lose support on Huawei mobile ...
Qiagen NV (NYSE: QGEN ) shares were spiking higher Monday following the announcement of FDA approval for its molecular diagnostic testing system. What Happened Germany-based Qiagen, a provider of sample ...
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Rome, L6, based Investment company Bank of Italy buys Qiagen NV during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Bank of Italy.